news
Pelacarsen slashed Lp(a) by 80% without cutting heart attacks
Novartis presented final results from the Lp(a)HORIZON phase 3 trial at the American Heart Association sessions, showing antisense drug pelacarsen reduced lipoprotein(a) by up to 80%. Despite the steep drop in over 8,000 high-risk patients, the injection failed to lower major cardiovascular events. The finding forces preventative cardiology to rethink whether clearing this genetic blood marker actually saves hearts.
Novartis presented final results from the Lp(a)HORIZON phase 3 trial at the American Heart Association sessions, showing antisense drug pelacarsen reduced lipoprotein(a) by up to 80%. Despite the steep drop in over 8,000 high-risk patients, the injection failed to lower major cardiovascular events. The finding forces preventative cardiology to rethink whether clearing this genetic blood marker actually saves hearts.
The architecture take
I spent the last three years convinced that clearing Lp(a) would be preventative medicine's next slam dunk. Every longevity clinician I talk to treats lipoprotein(a) like a ticking genetic clock, because regular diet, zone 2 cardio, and statins cannot nudge it down. Pelacarsen proved it can clear the protein out of the bloodstream with surgical precision. Yet when Novartis tracked actual cardiovascular events across thousands of high-risk patients, the hard outcomes refused to budge. That is a sobering reminder that moving a surrogate blood marker on a lab slip does not automatically change what happens inside an artery wall. I was wrong about how simple the vascular math would be. The drug makers will pivot toward earlier intervention windows or blame baseline vascular calcification (which happens after every failed phase three), but this stalls a multi-billion-dollar category. Boring habits still win. I am keeping my focus on sleep, daily movement, and endothelial health instead of waiting for a silver-bullet injection.